NTRK2 and central nervous system cancer: TrkB.T1 is also capable of enhancing downstream targets of PDGF signaling in vitro, including Akt, STAT3, and pS6 (Fig. 5), and future studies should explore if this is a PDGF-specific effect or a more general effect of TrkB.T1 exhibiting crosstalk with other receptor tyrosine kinases to explore whether this phenomenon may be applicable to other tumor types beyond gliomas.